TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
TG Therapeutics, Inc. Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60…
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
TG Therapeutics, Inc. 82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement…
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
TG Therapeutics, Inc. Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved…
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
TG Therapeutics, Inc. NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced…